Parsippany-Troy Hills, N.J.-based Allergan completed its acquisition of San Francisco-based Tobira Therapeutics.
Marlborough, Mass.-based Boston Scientific acquired the LumenR Tissue Retractor System from Newark, Calif.-based LumenR.
Osaka, Japan-based Takeda Pharmaceuticals and New York City-based technology company Koneksa Health partnered to integrate digital health tools into early-stage clinical trials.
Leverkusen, Germany-based Bayer submitted a new drug application to the FDA for Stivarga or Regorafenib, its second-line treatment for liver cancer patients.
A study in Cancer Medicine found that a new blood test developed by Bridgewater, N.J.-based Clinical Genomics is more sensitive than a standard carcinoembryonic antigen test when identifying colorectal cancer recurrence.
Data related to obeticholic acid will be presented at the American Association for the Study of Liver Diseases’ annual meeting. Obeticholic acid, commercially known as Ocaliva, is a prescription medication developed by Intercept Pharmaceuticals for the treatment of primary biliary cholangitis.
More articles on gastroenterology and endoscopy:
Clinical Genomics’ circulating tumor DNA blood test proves effective for CRC recurrence detection: 3 notes
Takeda Pharmaceuticals, Koneksa Health to introduce biosensors, wearable technology into clinical studies: 3 notes
Women’s cancer deaths to increase by 60% through 2030: 5 colorectal cancer findings
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.